New research confirms Lutetium-177-PSMA-617 is effective for advanced prostate cancer, even after Radium-223 treatment.
Vous n'êtes pas connecté
Lutetium-177-PSMA-617 (177Lu-PSMA-617), a type of targeted medlinkradiation therapy/medlink, is effective for men with advanced medlinkprostate
New research confirms Lutetium-177-PSMA-617 is effective for advanced prostate cancer, even after Radium-223 treatment.
Increasing omega-3 intake and decreasing omega-6 consumption could slow medlinkprostate cancer/medlink progress. A diet rich in omega-3 fats can...
Focused ultrasound therapy provides a non-invasive, promising treatment option for prostate cancer, offering hope with fewer side effects and...
TUESDAY, Feb. 18, 2025 -- For patients with advanced prostate cancer (aPC), completion of a 12-week supervised exercise regimen leads to a...
TUESDAY, Feb. 11, 2025 -- The 18-gene MyProstateScore 2.0 (MPS2) test using first-catch non-digital rectal examination (DRE) urine is highly...
Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious...
TUESDAY, Feb. 18, 2025 -- Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in...
Combining the small-molecule protein therapy TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) with focused ultrasound (FUS)...
A new study suggests that a combination of radiation therapy and immune checkpoint inhibitors (ICIs) may offer a less invasive alternative to bladder...
In a randomised clinical trial, researchers from Huntsman Cancer Institute at the University of Utah, USA, (the U) have found that short-course,...